Characteristics, treatment patterns, and survival from three cohorts of advanced or metastatic cancer patients using healthcare claims data in the United States.

• DOI: 10.1200/jco.2019.37.15_suppl.e13082
• Publication Date: 2019-05-27T15:57:32Z
• Authors: Francois-Xavier Lamy; Daniel C Beachler; Leo J Russo; Stephan Lanes; Jade Dinh; Devon H Taylor; Ruihua Yin; Aziza Jamal-Allial; Patrice Verpillat
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

e13082 Background: Our main objective was to identify, in healthcare claims data, patients with advanced or metastatic: urothelial carcinoma (amUC), gastric cancer (amGC) and non-small cell lung (amNSCLC) report on their characteristics, treatments, survival rates using contemporaneous real-world data. Methods: This cohort study conducted the HealthCore Integrated Research Database (HIRD), from January 2010 2018, which contains data commercial health plans across US (60 million lives). We applied algorithms, previously validated registry HIRD define 3 cohorts of stage cancer. Cohort characteristics treatment patterns were described. Patient vital status captured through probabilistic linkage National Death Index (NDI) assessed Kaplan-Meier method. Results: Algorithms predict resulted following cohorts: 1,501 amUC, 6,253 amGC 38,451 amNSCLC cases. Most each de novo metastatic, but subsets diagnosed at early progressed (ranging 15.1% for 23.1% amUC). treatments outcomes are described Table. Not all received systemic treatment; Immune Checkpoint inhibitors (ICI) used 5.3%, 2.2% 10.8% treated patients, respectively. Conclusions: In these metastatic median time limited despite most receiving treatment: radiation, therapy surgery. Treatment ICI low recent amUC amNSCLC. Characteristics, estimated date. [Table: see text]